Mr. Bill Zhang reports

DRI HEALTHCARE TRUST ANNOUNCES VOTING RESULTS OF ANNUAL AND SPECIAL MEETING

DRI Healthcare Trust has released results of voting at its annual and special meeting of unitholders held on May 15, 2026. All of the nominees for election as trustees of DRI Healthcare referred to in its management information circular dated April 13, 2026, were elected to serve as trustees for the ensuing year, Deloitte LLP was reappointed as the auditor of DRI Healthcare, and unitholders approved DRI Healthcare's carried interest plan and the first amendment to DRI Healthcare's omnibus equity incentive plan.

Election of trustees

Voting results for the election of each trustee were as follows.

Reappointment of auditor

Unitholders also voted in favour of reappointing Deloitte LLP as the auditor of DRI Healthcare and authorizing the board of trustees to fix its remuneration, with 99.85 per cent of votes cast in favour.

Carried interest plan

Unitholders approved DRI Healthcare's carried interest plan, with 91.87 per cent of votes cast in favour.

First amendment to omnibus equity incentive plan

Unitholders approved the first amendment to DRI Healthcare's omnibus equity incentive plan to increase the number of units reserved for issuance thereunder by a further one million units, with 71.71 per cent of votes cast in favour.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.